Media releases Keyword Search Clear 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 Published on: 19 October 2020 Roche announces full FDA approval for Venclexta combinations for acute myeloid leukaemia more Published on: 15 October 2020 First nine months of the year with 1% sales growth at constant exchange rates, significant impact of COVID-19 pandemic more Published on: 13 October 2020 Roche to launch laboratory SARS-CoV-2 antigen test to support high-volume testing of suspected COVID-19 patients more Published on: 28 September 2020 Roche presents new 2-year data for Evrysdi (risdiplam) in infants with Type 1 spinal muscular atrophy (SMA) more Published on: 19 September 2020 Roche presents new data from multiple Phase III studies of Tecentriq in triple-negative breast cancer at ESMO Virtual Congress 2020 more Published on: 18 September 2020 Roche receives positive CHMP opinion for Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer more Published on: 18 September 2020 Roche launches new quantitative antibody test to measure SARS-CoV-2 antibodies, to support the evaluation of vaccines more Published on: 18 September 2020 Roche’s phase III EMPACTA study showed Actemra/RoActemra reduced the likelihood of needing mechanical ventilation in hospitalised patients with COVID-19 associated pneumonia more Published on: 17 September 2020 Roche to present a broad range of data across multiple cancer types at the ESMO Virtual Congress 2020 more Published on: 16 September 2020 Roche receives FDA approval for expanded use of the CINtec PLUS Cytology test to aid clinicians in preventing cervical cancer more Published on: 11 September 2020 New data further reinforce Roche’s OCREVUS (ocrelizumab) as a highly effective treatment for people with multiple sclerosis more Published on: 10 September 2020 New data show Roche’s ENSPRYNG (satralizumab) significantly reduces severity and risk of relapse in neuromyelitis optica spectrum disorder (NMOSD) more Published on: 9 September 2020 Roche expands its multiple sclerosis portfolio with investigational BTK inhibitor fenebrutinib and initiates novel clinical trials for OCREVUS (ocrelizumab) more Published on: 8 September 2020 Roche receives FDA clearance for BK virus quantitative test on cobas 6800/8800 Systems to support better care for transplant patients more Published on: 7 September 2020 Roche announces FDA approval of Gavreto (pralsetinib) for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer more Published on: 4 September 2020 Roche receives FDA Emergency Use Authorization for the cobas SARS-CoV-2 & Influenza A/B Test for use on the cobas 6800/8800 Systems more Published on: 3 September 2020 Roche to present new data in multiple sclerosis and neuromyelitis optica spectrum disorder at MSVirtual2020 more Published on: 1 September 2020 Roche to launch SARS-CoV-2 Rapid Antigen Test in countries accepting CE mark, allowing fast triage decisions at point of care more Published on: 1 September 2020 Roche receives FDA approval for first HIV-1/HIV-2 Qualitative Test on the cobas 6800/8800 Systems in the fight against HIV/AIDS more Published on: 28 August 2020 Roche announces FDA approval of FoundationOne Liquid CDx, a comprehensive pan-tumour liquid biopsy test more Published on: 19 August 2020 Roche and Regeneron collaborate to significantly increase global supply of REGN-COV2 investigational antibody combination for COVID-19 more Published on: 17 August 2020 FDA Approves Roche’s ENSPRYNG for Neuromyelitis Optica Spectrum Disorder (NMOSD) more Published on: 10 August 2020 FDA approves Roche’s Evrysdi (risdiplam) for treatment of spinal muscular atrophy (SMA) in adults and children 2 months and older more Published on: 10 August 2020 Roche provides update on phase III studies of etrolizumab in people with moderately to severely active ulcerative colitis more Published on: 6 August 2020 Roche provides update on Phase III study of Tecentriq in combination with paclitaxel for people with metastatic triple-negative breast cancer more Published on: 5 August 2020 Roche announces FDA authorisation for the first Epstein-Barr virus quantitative test on the cobas 6800/8800 Systems to improve care for transplant patients more Published on: 3 August 2020 Rozlytrek, Roche’s first tumour-agnostic therapy, approved in Europe for people with NTRK fusion-positive solid tumours and for people with ROS1-positive advanced non-small cell lung cancer more Published on: 31 July 2020 FDA approves Roche’s Tecentriq plus Cotellic and Zelboraf for people with advanced melanoma more Published on: 29 July 2020 FDA approves Roche’s new VENTANA HER2 Dual ISH test as companion diagnostic to identify breast cancer patients eligible for targeted therapy more Published on: 29 July 2020 Roche provides an update on the phase III COVACTA trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 associated pneumonia more Published on: 23 July 2020 First half of the year with 1% growth at constant exchange rates, significant impact of COVID-19 pandemic more Published on: 22 July 2020 Phase III data show Roche’s Port Delivery System with ranibizumab enabled over 98% of patients to go six months between treatments for neovascular age-related macular degeneration more Published on: 14 July 2020 Roche collaborates with Blueprint Medicines to bring a new treatment to people with RET-altered cancers more Published on: 13 July 2020 New data from phase IIIb study reinforces safety profile of Roche’s Hemlibra in people with haemophilia A more Published on: 13 July 2020 Roche provides update on Phase III study of Tecentriq in women with advanced stage ovarian cancer more Published on: 29 June 2020 FDA approves Roche’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for HER2-positive breast cancer more Published on: 29 June 2020 Roche announces new data at the ISTH 2020 Congress, demonstrating ongoing commitment to advancing care for people with haemophilia A more Published on: 29 June 2020 Roche’s ENSPRYNG®️ (satralizumab) approved in Japan for adults and children with neuromyelitis optica spectrum disorder more Published on: 26 June 2020 Roche improves speed and accuracy of non-small cell lung cancer diagnosis with launch of automated digital pathology algorithm more Published on: 19 June 2020 Roche’s IPATential150 study evaluating ipatasertib in combination with abiraterone and prednisone/prednisolone met one of its co-primary endpoints more Published on: 18 June 2020 Roche’s Tecentriq in combination with chemotherapy (including Abraxane) meets primary endpoint of improved pathological complete response, regardless of PD-L1 status, as initial treatment for people with early triple-negative breast cancer more Published on: 13 June 2020 Positive phase III results for Venclexta/Venclyxto combination in acute myeloid leukaemia presented at EHA 2020 more Published on: 12 June 2020 Roche announces 2-year risdiplam data from SUNFISH and new data from JEWELFISH in infants, children and adults with spinal muscular atrophy (SMA) more Published on: 4 June 2020 Roche’s Elecsys IL-6 test receives FDA Emergency Use Authorization to help in identifying patients at high risk of severe inflammatory response more Published on: 2 June 2020 FDA approves Roche’s Tecentriq in combination with Avastin for people with the most common form of liver cancer more Published on: 29 May 2020 CHMP recommends EU approval of Roche’s Rozlytrek for people with NTRK fusion-positive solid tumours and for people with ROS1-positive, advanced non-small cell lung cancer more Published on: 29 May 2020 Updated data demonstrate Roche’s Alecensa increases overall survival rate for people with ALK-positive non-small cell lung cancer more Published on: 28 May 2020 Roche’s OCREVUS (ocrelizumab) shorter 2-hour infusion time approved in Europe more Published on: 28 May 2020 Roche initiates phase III clinical trial of Actemra/RoActemra plus remdesivir in hospitalised patients with severe COVID-19 pneumonia more Published on: 27 May 2020 Roche’s Port Delivery System with ranibizumab shows positive phase III results in neovascular age-related macular degeneration more Published on: 22 May 2020 Roche acquires Stratos Genomics to further develop DNA based sequencing for diagnostic use more Published on: 22 May 2020 New longer-term data reinforce safety of Roche’s satralizumab in adults and adolescents with neuromyelitis optica spectrum disorder more Published on: 19 May 2020 FDA approves Roche’s Tecentriq as a first-line monotherapy for certain people with metastatic non-small cell lung cancer more Published on: 15 May 2020 Roche launches new blood gas digital solution designed to improve patient care more Published on: 14 May 2020 Roche to present first clinical data on novel anti-TIGIT cancer immunotherapy tiragolumab at ASCO more Published on: 11 May 2020 A formative figure in the company's history: Roche Honorary Chairman Fritz Gerber dies at the age of 91 more Published on: 11 May 2020 Changes to the Roche Enlarged Corporate Executive Committee more Published on: 7 May 2020 New data at the ASCO20 Virtual Scientific Program reflects Roche’s commitment to accelerating progress in cancer care more Published on: 3 May 2020 Roche’s COVID-19 antibody test receives FDA Emergency Use Authorization and is available in markets accepting the CE mark more Published on: 28 April 2020 New 6-year data for Roche’s OCREVUS (ocrelizumab) show earlier treatment initiation nearly halves risk of needing walking aid in relapsing multiple sclerosis more Published on: 28 April 2020 Roche’s risdiplam shows significant improvement in survival and motor milestones in infants with Type 1 spinal muscular atrophy (SMA) more Published on: 22 April 2020 First quarter with 2% growth in Swiss francs, 7% at constant exchange rates more Published on: 21 April 2020 Roche receives FDA approval for cobas HPV test for use on the cobas 6800/8800 Systems to identify women at risk for cervical cancer more Published on: 20 April 2020 US FDA and EMA accept applications for Roche’s OCREVUS (ocrelizumab) shorter 2-hour infusion time more Published on: 17 April 2020 Roche develops new serology test to detect COVID-19 antibodies more Published on: 7 April 2020 Roche provides regulatory update on risdiplam for the treatment of spinal muscular atrophy (SMA) more Published on: 24 March 2020 Roche response to COVID-19 pandemic more Published on: 23 March 2020 Roche announces Venclexta/Venclyxto combination improved overall survival in people with previously untreated acute myeloid leukaemia more Published on: 19 March 2020 Roche initiates Phase III clinical trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 pneumonia more Published on: 17 March 2020 Roche Annual General Meeting 2020 more Published on: 16 March 2020 Roche Annual General Meeting 2020: Voting will take place by independent proxy. Participation on site is neither possible nor permitted by Federal Council ordinance more Published on: 14 March 2020 Roche Annual General Meeting 2020 to take place under special conditions set by the authorities - electronic voting strongly recommended more Published on: 13 March 2020 Roche’s cobas SARS-CoV-2 Test to detect novel coronavirus receives FDA Emergency Use Authorization and is available in markets accepting the CE mark more Published on: 12 March 2020 European Commission approves Venclyxto plus Gazyvaro for adults with previously untreated chronic lymphocytic leukaemia more Published on: 11 March 2020 Roche receives FDA approval for CINtec PLUS Cytology test to aid clinicians in improving cervical cancer prevention more Published on: 4 March 2020 FDA grants Breakthrough Device Designation for Roche's Elecsys GALAD score to support earlier diagnosis of hepatocellular carcinoma more Published on: 25 February 2020 FDA accepts Roche’s Biologics License Application for fixed-dose subcutaneous combination of Perjeta and Herceptin for HER2-positive breast cancer more Published on: 19 February 2020 FDA grants priority review to Roche’s Tecentriq monotherapy as first-line treatment of certain people with advanced non-small cell lung cancer more Published on: 14 February 2020 China National Medical Products Administration grants approval of Roche’s Tecentriq in combination with chemotherapy as first-line treatment of people with extensive-stage small cell lung cancer more Published on: 10 February 2020 Roche provides topline results from investigator-led Phase II/III trial with gantenerumab in rare inherited form of Alzheimer’s disease more Published on: 6 February 2020 Roche’s risdiplam showed significant improvement in motor function in people aged 2-25 with type 2 or 3 spinal muscular atrophy more Published on: 30 January 2020 Roche reports very strong results in 2019 more Published on: 27 January 2020 Roche submits supplemental Biologics License Application to the FDA for Tecentriq in combination with Avastin for the most common form of liver cancer more Published on: 24 January 2020 Roche provides an update on Phase III study of Tecentriq in people with muscle-invasive urothelial cancer more Published on: 23 January 2020 Roche’s Risdiplam meets primary endpoint in pivotal FIREFISH trial in infants with type 1 spinal muscular atrophy more Published on: 21 January 2020 European Commission approves Roche’s Polivy for people with previously treated aggressive lymphoma more Published on: 13 January 2020 Roche and Illumina partner to broaden patient access to genomic testing more
Published on: 19 October 2020 Roche announces full FDA approval for Venclexta combinations for acute myeloid leukaemia more
Published on: 15 October 2020 First nine months of the year with 1% sales growth at constant exchange rates, significant impact of COVID-19 pandemic more
Published on: 13 October 2020 Roche to launch laboratory SARS-CoV-2 antigen test to support high-volume testing of suspected COVID-19 patients more
Published on: 28 September 2020 Roche presents new 2-year data for Evrysdi (risdiplam) in infants with Type 1 spinal muscular atrophy (SMA) more
Published on: 19 September 2020 Roche presents new data from multiple Phase III studies of Tecentriq in triple-negative breast cancer at ESMO Virtual Congress 2020 more
Published on: 18 September 2020 Roche receives positive CHMP opinion for Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer more
Published on: 18 September 2020 Roche launches new quantitative antibody test to measure SARS-CoV-2 antibodies, to support the evaluation of vaccines more
Published on: 18 September 2020 Roche’s phase III EMPACTA study showed Actemra/RoActemra reduced the likelihood of needing mechanical ventilation in hospitalised patients with COVID-19 associated pneumonia more
Published on: 17 September 2020 Roche to present a broad range of data across multiple cancer types at the ESMO Virtual Congress 2020 more
Published on: 16 September 2020 Roche receives FDA approval for expanded use of the CINtec PLUS Cytology test to aid clinicians in preventing cervical cancer more
Published on: 11 September 2020 New data further reinforce Roche’s OCREVUS (ocrelizumab) as a highly effective treatment for people with multiple sclerosis more
Published on: 10 September 2020 New data show Roche’s ENSPRYNG (satralizumab) significantly reduces severity and risk of relapse in neuromyelitis optica spectrum disorder (NMOSD) more
Published on: 9 September 2020 Roche expands its multiple sclerosis portfolio with investigational BTK inhibitor fenebrutinib and initiates novel clinical trials for OCREVUS (ocrelizumab) more
Published on: 8 September 2020 Roche receives FDA clearance for BK virus quantitative test on cobas 6800/8800 Systems to support better care for transplant patients more
Published on: 7 September 2020 Roche announces FDA approval of Gavreto (pralsetinib) for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer more
Published on: 4 September 2020 Roche receives FDA Emergency Use Authorization for the cobas SARS-CoV-2 & Influenza A/B Test for use on the cobas 6800/8800 Systems more
Published on: 3 September 2020 Roche to present new data in multiple sclerosis and neuromyelitis optica spectrum disorder at MSVirtual2020 more
Published on: 1 September 2020 Roche to launch SARS-CoV-2 Rapid Antigen Test in countries accepting CE mark, allowing fast triage decisions at point of care more
Published on: 1 September 2020 Roche receives FDA approval for first HIV-1/HIV-2 Qualitative Test on the cobas 6800/8800 Systems in the fight against HIV/AIDS more
Published on: 28 August 2020 Roche announces FDA approval of FoundationOne Liquid CDx, a comprehensive pan-tumour liquid biopsy test more
Published on: 19 August 2020 Roche and Regeneron collaborate to significantly increase global supply of REGN-COV2 investigational antibody combination for COVID-19 more
Published on: 17 August 2020 FDA Approves Roche’s ENSPRYNG for Neuromyelitis Optica Spectrum Disorder (NMOSD) more
Published on: 10 August 2020 FDA approves Roche’s Evrysdi (risdiplam) for treatment of spinal muscular atrophy (SMA) in adults and children 2 months and older more
Published on: 10 August 2020 Roche provides update on phase III studies of etrolizumab in people with moderately to severely active ulcerative colitis more
Published on: 6 August 2020 Roche provides update on Phase III study of Tecentriq in combination with paclitaxel for people with metastatic triple-negative breast cancer more
Published on: 5 August 2020 Roche announces FDA authorisation for the first Epstein-Barr virus quantitative test on the cobas 6800/8800 Systems to improve care for transplant patients more
Published on: 3 August 2020 Rozlytrek, Roche’s first tumour-agnostic therapy, approved in Europe for people with NTRK fusion-positive solid tumours and for people with ROS1-positive advanced non-small cell lung cancer more
Published on: 31 July 2020 FDA approves Roche’s Tecentriq plus Cotellic and Zelboraf for people with advanced melanoma more
Published on: 29 July 2020 FDA approves Roche’s new VENTANA HER2 Dual ISH test as companion diagnostic to identify breast cancer patients eligible for targeted therapy more
Published on: 29 July 2020 Roche provides an update on the phase III COVACTA trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 associated pneumonia more
Published on: 23 July 2020 First half of the year with 1% growth at constant exchange rates, significant impact of COVID-19 pandemic more
Published on: 22 July 2020 Phase III data show Roche’s Port Delivery System with ranibizumab enabled over 98% of patients to go six months between treatments for neovascular age-related macular degeneration more
Published on: 14 July 2020 Roche collaborates with Blueprint Medicines to bring a new treatment to people with RET-altered cancers more
Published on: 13 July 2020 New data from phase IIIb study reinforces safety profile of Roche’s Hemlibra in people with haemophilia A more
Published on: 13 July 2020 Roche provides update on Phase III study of Tecentriq in women with advanced stage ovarian cancer more
Published on: 29 June 2020 FDA approves Roche’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for HER2-positive breast cancer more
Published on: 29 June 2020 Roche announces new data at the ISTH 2020 Congress, demonstrating ongoing commitment to advancing care for people with haemophilia A more
Published on: 29 June 2020 Roche’s ENSPRYNG®️ (satralizumab) approved in Japan for adults and children with neuromyelitis optica spectrum disorder more
Published on: 26 June 2020 Roche improves speed and accuracy of non-small cell lung cancer diagnosis with launch of automated digital pathology algorithm more
Published on: 19 June 2020 Roche’s IPATential150 study evaluating ipatasertib in combination with abiraterone and prednisone/prednisolone met one of its co-primary endpoints more
Published on: 18 June 2020 Roche’s Tecentriq in combination with chemotherapy (including Abraxane) meets primary endpoint of improved pathological complete response, regardless of PD-L1 status, as initial treatment for people with early triple-negative breast cancer more
Published on: 13 June 2020 Positive phase III results for Venclexta/Venclyxto combination in acute myeloid leukaemia presented at EHA 2020 more
Published on: 12 June 2020 Roche announces 2-year risdiplam data from SUNFISH and new data from JEWELFISH in infants, children and adults with spinal muscular atrophy (SMA) more
Published on: 4 June 2020 Roche’s Elecsys IL-6 test receives FDA Emergency Use Authorization to help in identifying patients at high risk of severe inflammatory response more
Published on: 2 June 2020 FDA approves Roche’s Tecentriq in combination with Avastin for people with the most common form of liver cancer more
Published on: 29 May 2020 CHMP recommends EU approval of Roche’s Rozlytrek for people with NTRK fusion-positive solid tumours and for people with ROS1-positive, advanced non-small cell lung cancer more
Published on: 29 May 2020 Updated data demonstrate Roche’s Alecensa increases overall survival rate for people with ALK-positive non-small cell lung cancer more
Published on: 28 May 2020 Roche’s OCREVUS (ocrelizumab) shorter 2-hour infusion time approved in Europe more
Published on: 28 May 2020 Roche initiates phase III clinical trial of Actemra/RoActemra plus remdesivir in hospitalised patients with severe COVID-19 pneumonia more
Published on: 27 May 2020 Roche’s Port Delivery System with ranibizumab shows positive phase III results in neovascular age-related macular degeneration more
Published on: 22 May 2020 Roche acquires Stratos Genomics to further develop DNA based sequencing for diagnostic use more
Published on: 22 May 2020 New longer-term data reinforce safety of Roche’s satralizumab in adults and adolescents with neuromyelitis optica spectrum disorder more
Published on: 19 May 2020 FDA approves Roche’s Tecentriq as a first-line monotherapy for certain people with metastatic non-small cell lung cancer more
Published on: 15 May 2020 Roche launches new blood gas digital solution designed to improve patient care more
Published on: 14 May 2020 Roche to present first clinical data on novel anti-TIGIT cancer immunotherapy tiragolumab at ASCO more
Published on: 11 May 2020 A formative figure in the company's history: Roche Honorary Chairman Fritz Gerber dies at the age of 91 more
Published on: 7 May 2020 New data at the ASCO20 Virtual Scientific Program reflects Roche’s commitment to accelerating progress in cancer care more
Published on: 3 May 2020 Roche’s COVID-19 antibody test receives FDA Emergency Use Authorization and is available in markets accepting the CE mark more
Published on: 28 April 2020 New 6-year data for Roche’s OCREVUS (ocrelizumab) show earlier treatment initiation nearly halves risk of needing walking aid in relapsing multiple sclerosis more
Published on: 28 April 2020 Roche’s risdiplam shows significant improvement in survival and motor milestones in infants with Type 1 spinal muscular atrophy (SMA) more
Published on: 22 April 2020 First quarter with 2% growth in Swiss francs, 7% at constant exchange rates more
Published on: 21 April 2020 Roche receives FDA approval for cobas HPV test for use on the cobas 6800/8800 Systems to identify women at risk for cervical cancer more
Published on: 20 April 2020 US FDA and EMA accept applications for Roche’s OCREVUS (ocrelizumab) shorter 2-hour infusion time more
Published on: 7 April 2020 Roche provides regulatory update on risdiplam for the treatment of spinal muscular atrophy (SMA) more
Published on: 23 March 2020 Roche announces Venclexta/Venclyxto combination improved overall survival in people with previously untreated acute myeloid leukaemia more
Published on: 19 March 2020 Roche initiates Phase III clinical trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 pneumonia more
Published on: 16 March 2020 Roche Annual General Meeting 2020: Voting will take place by independent proxy. Participation on site is neither possible nor permitted by Federal Council ordinance more
Published on: 14 March 2020 Roche Annual General Meeting 2020 to take place under special conditions set by the authorities - electronic voting strongly recommended more
Published on: 13 March 2020 Roche’s cobas SARS-CoV-2 Test to detect novel coronavirus receives FDA Emergency Use Authorization and is available in markets accepting the CE mark more
Published on: 12 March 2020 European Commission approves Venclyxto plus Gazyvaro for adults with previously untreated chronic lymphocytic leukaemia more
Published on: 11 March 2020 Roche receives FDA approval for CINtec PLUS Cytology test to aid clinicians in improving cervical cancer prevention more
Published on: 4 March 2020 FDA grants Breakthrough Device Designation for Roche's Elecsys GALAD score to support earlier diagnosis of hepatocellular carcinoma more
Published on: 25 February 2020 FDA accepts Roche’s Biologics License Application for fixed-dose subcutaneous combination of Perjeta and Herceptin for HER2-positive breast cancer more
Published on: 19 February 2020 FDA grants priority review to Roche’s Tecentriq monotherapy as first-line treatment of certain people with advanced non-small cell lung cancer more
Published on: 14 February 2020 China National Medical Products Administration grants approval of Roche’s Tecentriq in combination with chemotherapy as first-line treatment of people with extensive-stage small cell lung cancer more
Published on: 10 February 2020 Roche provides topline results from investigator-led Phase II/III trial with gantenerumab in rare inherited form of Alzheimer’s disease more
Published on: 6 February 2020 Roche’s risdiplam showed significant improvement in motor function in people aged 2-25 with type 2 or 3 spinal muscular atrophy more
Published on: 27 January 2020 Roche submits supplemental Biologics License Application to the FDA for Tecentriq in combination with Avastin for the most common form of liver cancer more
Published on: 24 January 2020 Roche provides an update on Phase III study of Tecentriq in people with muscle-invasive urothelial cancer more
Published on: 23 January 2020 Roche’s Risdiplam meets primary endpoint in pivotal FIREFISH trial in infants with type 1 spinal muscular atrophy more
Published on: 21 January 2020 European Commission approves Roche’s Polivy for people with previously treated aggressive lymphoma more
Published on: 13 January 2020 Roche and Illumina partner to broaden patient access to genomic testing more